For this purpose, we evaluated 97 tumor samples (90 breast and seven ovarian) from carriers of 26 distinct BRCA1 germline variants (ten PV, eight VUS, and eight BV) using a pipeline (pyrosequencing, NGS, methylation, and BRCAness analysis) to identify genomic markers of BRCA1 locus-specific LOH and other possible mechanisms of gene inactivation. Here, BRCA1 is linked to neoplasm.